相关实验视频

Updated: Jan 17, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

利用结构-活性关系,将FLAP抑制剂BRP-7重新用于强效和选择性SEH抑制剂

Kübra Çalışkan¹, Mehmet Karataş¹, Paul M Jordan²

¹Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University, Taç Sok. No:3 Yenimahalle, 06560, Ankara, Turkey.

Bioorganic chemistry

|September 20, 2025

概括

研究人员开发了基于胺的新型胺基,作为强大的可溶性环氧化酶 (sEH) 抑制剂. 化合物FP30表现出卓越的活性和稳定性,为治疗炎症疾病和神经病痛提供了有前途的支架.

科学领域:

药用化学医学化学
药理学药理学是指药理学的学科.
生物化学生物化学

背景情况:

溶性环氧化酶 (sEH) 是一种有效的治疗点,用于治疗炎症,包括心血管,代谢和中枢神经系统疾病.
现有的抑制剂可能缺乏选择性或最佳的药理动力学特性.

研究的目的:

设计,合成和评估一种新的类型的基于本齐米达的胺衍生物作为强效和选择性的SEH抑制剂.
为了识别用于sEH向治疗的新化学支架.

主要方法:

基于SAR洞察力的合理药物设计和支架优化.
合成基于本齐米达的胺衍生物.
在体外生物评估,包括sEH抑制测定,代谢稳定性研究 (人肝显微体) 和可溶性评估.
对FLAP (5-lipoxygenase激活蛋白) 的选择性分析.

主要成果:

FP30 (BRP-821),一种新型的西米达衍生物,显示出强大的sEH抑制,IC50为0.4nM.
FP30表现出极好的代谢稳定性 (t1/2>184分钟) 和高溶解度 (108微米).
合成的化合物对sEH比FLAP具有很高的选择性,使其与双重抑制剂有所区别.

结论:

开发的基于本齐米达的胺体代表了对sEH抑制的有前途的新化学型.
FP30是一种具有治疗潜力的强效,选择性和代谢稳定的sEH抑制剂.
这种支架需要进一步优化,以开发治疗神经病痛和炎症疾病的新疗法.

关键词:

西米达 (Benzimidazole) 是一种一种环氧化酸酶是一种环氧化酶.脂肪酸是一种脂肪酸.炎症炎症是一种炎症.疼痛疼痛疼痛疼痛

更多相关视频

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

相关概念视频

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...